De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Twist Bioscience Beheer
Beheer criteriumcontroles 3/4
De CEO Twist Bioscience's is Emily Leproust, benoemd in Apr2013, heeft een ambtstermijn van 11.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.00M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.39% van de aandelen van het bedrijf, ter waarde $ 10.42M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 7.9 jaar.
Belangrijke informatie
Emily Leproust
Algemeen directeur
US$8.0m
Totale compensatie
| Percentage CEO-salaris | 8.6% |
| Dienstverband CEO | 11.5yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 3.4yrs |
| Gemiddelde ambtstermijn bestuur | 7.9yrs |
Recente managementupdates
Recent updates
Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Sep 25
Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues
Aug 20Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Aug 04Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Jul 26We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jun 10Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth
May 04Twist Bioscience: NGS Is Taking Off
May 03Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses
Sep 16Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play
Sep 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$220m |
| Mar 31 2024 | n/a | n/a | -US$192m |
| Dec 31 2023 | n/a | n/a | -US$206m |
| Sep 30 2023 | US$8m | US$685k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | n/a | n/a | -US$214m |
| Sep 30 2022 | US$6m | US$665k | -US$218m |
| Jun 30 2022 | n/a | n/a | -US$208m |
| Mar 31 2022 | n/a | n/a | -US$188m |
| Dec 31 2021 | n/a | n/a | -US$165m |
| Sep 30 2021 | US$1m | US$590k | -US$152m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | n/a | n/a | -US$117m |
| Sep 30 2020 | US$7m | US$519k | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$147m |
| Mar 31 2020 | n/a | n/a | -US$147m |
| Dec 31 2019 | n/a | n/a | -US$141m |
| Sep 30 2019 | US$8m | US$477k | -US$108m |
| Jun 30 2019 | n/a | n/a | -US$96m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | n/a | n/a | -US$77m |
| Sep 30 2018 | US$525k | US$362k | -US$71m |
Compensatie versus markt: De totale vergoeding ($USD 8.00M ) Emily } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van Emily is gestegen terwijl het bedrijf verliesgevend is.
CEO
Emily Leproust (51 yo)
11.5yrs
Tenure
US$7,998,637
Compensatie
Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.5yrs | US$8.00m | 0.39% $ 10.0m | |
| President & COO | 2yrs | US$5.23m | 0.085% $ 2.2m | |
| Senior Vice President of Human Resources | 8.6yrs | US$2.49m | 0.039% $ 994.7k | |
| Senior VP of Advanced Development | 4.8yrs | US$2.82m | 0.44% $ 11.2m | |
| Chief Financial Officer | less than a year | geen gegevens | 0.0029% $ 74.8k | |
| VP & Chief Accounting Officer | 1.4yrs | geen gegevens | 0.012% $ 309.3k | |
| Chief Technology Officer | 3.7yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 3.7yrs | geen gegevens | geen gegevens | |
| Chief Information Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Senior VP | 3.1yrs | US$1.96m | 0.050% $ 1.3m | |
| Chief ESG Officer & Senior VP of Corporate Affairs | 3.7yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Operations | less than a year | geen gegevens | geen gegevens |
3.4yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TWST wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 11.5yrs | US$8.00m | 0.39% $ 10.0m | |
| Senior VP of Advanced Development | 11.5yrs | US$2.82m | 0.44% $ 11.2m | |
| Independent Director | 11yrs | US$272.49k | 0.16% $ 4.1m | |
| Lead Independent Director | 10.3yrs | US$303.98k | 0.11% $ 2.8m | |
| Independent Director | 5.4yrs | US$284.99k | 0.030% $ 773.4k | |
| Independent Director | 7.9yrs | US$271.34k | 0.023% $ 588.8k | |
| Independent Director | 6yrs | US$284.99k | 0.020% $ 502.8k | |
| Independent Director | 3.2yrs | US$276.61k | 0.019% $ 471.1k | |
| Independent Director | 6.3yrs | US$269.99k | 0.043% $ 1.1m |
7.9yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TWST wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).